Lilly Hikes Mounjaro Prices in Canada After Initial Cuts

Price Movement Following Initial Reductions

The pharmaceutical company had previously reduced prices for both Mounjaro and Zepbound by 20% or more in December 2025, with four-week supplies falling to as low as $300 CAD. Current pricing data shows Mounjaro starting at $301 monthly, while Zepbound begins at $435 monthly across Canadian pharmacies.

Regulatory Resubmission Plans

Company representatives indicated that Lilly is finalizing plans to resubmit both Mounjaro and Zepbound to Canada's drug review agency in 2025. The resubmission process relates to expanded coverage considerations for public drug plans, which could affect patient access through provincial insurance programs.

Market Context and Competition

The pricing adjustment comes as generic competition looms for GLP-1 medications in Canada. Health Canada is currently reviewing nine generic semaglutide applications, with approvals expected by summer 2026. Semaglutide patents expired January 4, 2026, potentially creating pricing pressure across the entire GLP-1 class.

Both Mounjaro and Zepbound contain tirzepatide and are manufactured by Eli Lilly. Current Canadian pharmacy pricing varies significantly, with monthly costs ranging from $300 to $570 depending on strength, quantity, and pharmacy location.

Usage Statistics

Recent survey data indicates approximately 3 million Canadian adults currently use GLP-1 medications, including Ozempic, Mounjaro, and other brands. This represents substantial market demand that continues to strain employer drug plan budgets nationwide.

The price increase affects cash-paying patients directly, while those with private insurance coverage may see changes in copayment amounts depending on their specific plan structure. Patients can track current pricing across Canadian pharmacies using our insurance coverage checker tool.

Generic Timeline Impact

The timing of Lilly's price adjustment coincides with increasing anticipation for generic semaglutide tracker approvals. Multiple generic manufacturers, including Apotex, Sandoz, and Teva, have applications under Health Canada review with decisions expected in the coming months.

Industry analysts suggest brand manufacturers may be optimizing pricing strategies ahead of generic competition, which historically reduces branded drug prices by 65% or more once alternatives enter the market.